研究表明,在eGFR<30 mL/min/1.73m^2的CKD 4期患者中(无论是否患有2型糖尿病),达格列净在降低主要肾脏和心血管事件风险以及延缓eGFR降低方面的疗效与在整体队列中观察到的一致,没有证据表明会增加安全相关风险。 目前,通常不推荐肾功能...
由此研究可推出eGFR斜率的变化可能导致糖尿病患者罹患CKD的风险增加,且ESKD的发生风险亦会增加,这为未来在临床对于患者危险分层的预测价值提供了重要参考指标,eGFR斜率有望成为更好的该类患者分层指标,然而尚无关于eGFR斜率的中国人群相关大型...
慢性肾脏病(CKD)是一种以肾功能逐渐下降为特征的综合征,全世界约有10%-15%的人口罹患该病。这些患者尤其是终末期肾病(ESKD)患者肾功能下降几近消失,患者往往需要肾脏替代治疗如血液透析才能维持生命。患有ESKD的患者死亡率和心血管事件发生率大大增加增加,肾脏替代治疗对该类患者虽属必要但大大降低了生活质量。此外...
但与年龄相关的肾功能下降(生理器官衰老)与进展性 CKD 对健康具有不同的影响。随着全球 65 岁或 65 岁以上人群的持续增长,对老年 CKD 过度诊断的担忧日益增加。现有数据显示,CKD 患病率的增加与终末期肾病发病率的成比例增加无关,而且在特定的 eGFR 阈值下的风险因年龄组而异。因此,有必要对 CKD 进行年龄适应...
Changes in albuminuria, eGFR may serve as clinical end points in early stage CKDWebb, Melissa J.Nephrology News & Issues
Free GFR estimation using MDRD, CKD-EPI & Cockcroft-Gault formulas. Hospital-grade accuracy for patients & clinicians. Instant CKD staging with WHO guidelines.
eGFR for patients with an eGFRSCrof 30-59 mL/min/1.73m2to confirm or rule out stage 3 CKD; in those with conditions known to affect eGFRSCr; and in those with conditions that place them at increased risk for CKD progression such as diabetes,hypertension, cardiovascular disease, orheart ...
The genetic architecture of chronic kidney disease (CKD) is complex, including monogenic and polygenic contributions. CKD progression to kidney failure is
significantlYdecreasedinCKDstage 3 group(尸<O.01),stage4group(P <O.01)andstage5group(P<0.01).TherewasnodifferencebetweenCKD stagelgroupandstage 2 group(P>0.05).ABIvaluewasSignifleantlY decreasedwithgradualdeclineof’e(;FRlevel(P(O.01) 3.TherewereSignificantdiff’erencesinPWVVHIuebetween5 grou...
CKD has a prevalence of 15% and affects 30 million people in the US4,5. In addition to the risk of progressing to end-stage-renal disease (ESRD), CKD is associated with significant cardiovascular morbidity and mortality6,7. Patients with an eGFR of <15 ml/min/1.73 m2, for ...